R & D
DIS™ has access to a state-of-the-art biomarker discovery platform, enabling the company to identify and validate novel biomarkers predictive for cardiovascular diseases.
DIS™ identified a panel of differentially expressed exosomal biomarkers. The predictive power of this panel for adverse cardiovascular events is confirmed in large validation studies.
DIS™ recognizes the increasing need for novel biomarkers to assess cardiovascular risk and acknowledges the rigourous requirements to prove their value in clinical practice. Recently the
American Heart Association (AHA)
published a set of guidelines proposing standards for the critical appraisal of novel biomarkers.
R & D
DIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. The company's mission is to identify patients at risk of developing heart attacks and strokes. Our ultimate goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.
View the most recent papers related to CA
1217 KZ Hilversum,
t. +31 (0)6 51 94 75 22
buy cheap Super Avana
best sex with Tadora
Silagra sans ordonnance
buy Eriacta cheap online
R & D
EMC Biomedical Fund
. All rights reserved.